Striking example of the uncommon but aggressive Sarcomatoid Chromophobe renal cell carcinoma #gupath #pathology #urology #kidneycancer Michigan Pathology

Another amazing example of renomedullary interstitial cell tumor (medullary fibroma)- commonest kidney tumor of adults; bland spindle/stellate cells in myxoid stroma with stromal sclerosis #kidneymonth #KidneyCancerAwarenessMonth Michigan Pathology #gupath #pathology

Visual Intelligence feature that comes with iPhone 16…

Dr Martignoni highlighting study by Sounak Gupta John Cheville detailing molecular features underlying aggressive epithelioid AML #ECP2024 International Society of Urological Pathology GU Pathology Society (GUPS) #gupath #kidney

Final analysis of the ph3 Litespark -005 trial with belzutifan in mRCC #kidneycancer at the #ESMO24 ESMO - Eur. Oncology by Brian Rini, MD 👉PFS remains significant👇OS is similar in both arms. Final conclusion 👇Tom Powles KidneyCAN UroToday.com IKCC Kidney Cancer Uromigos OncoAlert

A novel HIF-2 alpha inhibitor, NKT2152 in mRCC #kidneycancer in #ESMO24 ESMO - Eur. Oncology 👉 encouraging efficacy and safety in this ph1/2 trial of heavily treated patients. Conclusions 👇Excellent talk by Eric Jonasch MD Anderson Cancer Center Toni Choueiri, MD OncoAlert KidneyCAN UroToday.com

Congratulations Andrea Apolo, M.D. and the @alliance team for the ph 3 Ambassador trial data showing improved disease free survival with pembrolizumab in MIBC after surgery #bladdercancer 👇Terrific presentation and Simultaneously published NEJM paper👇 ESMO - Eur. Oncology #ESMO24 OncoAlert

Fecal microbiota transplantation doubles objective response with systemic therapy in mRCC #kidneycancer (axitinib+ pembrolizumab). 👇 Congrats Chiara for the wonderful talk (validates data from Nazli Dizman Sumanta K. Pal, MD, FASCO ) ESMO - Eur. Oncology #ESMO24 OncoAlert KidneyCAN UroToday.com

Nectin-4 is the target for Enfortumab Vedotin and is widely expressed in UC (median 275/300) . EV302 is 1st randomised trial to explore its relationship with response. IHC results show no clear relationship between Nectin-4 and outcome (RR,PFS,OS) or PD-L1 #ESMO2024

Nectin4 and PDL1 are not predictive of EV pembro efficacy in metastatic #bladdercancer. It continues to be the first line therapy standard of care for patients who are eligible. #ESMO2024 OncoAlert

Amazing overview of non-clear cell #kidneycancer by Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr at #ESMO24. Spanning #papillary, #chromophobe, #collectingduct, #RMC & multiple other subtypes, he eloquently provides perspective on optimal management based on available data for each disease state. The

Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone. Full NIAGARA trial results: nej.md/4gmAqk3 #ESMO24

‘SHOGUN’ has won 18 Emmys, an all-time record for a single season of TV. • Best Drama • Best Directing • Best Sound Mixing • Best Sound Editing • Best Picture Editing • Best Cinematography • Best Period Costumes • Best Main Title Design • Best Production Design • Best

Platinum Priority: Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review by Adam B. Weiner, MD et al Read the full article here: buff.ly/3z5AiVD #UroSoMe #MedTwitter #ProstateCancer #PCa #EuroUrol Andrew Armstrong

Appreciate the shoutout and steadfast support! Grateful to have so many wonderful colleagues at MD Anderson Cancer Center who are passionate about #rarecancers. Helping patients with these diseases is immensely gratifying and provides invaluable insights for other rare & common conditions.

This is a direct example of how focused bench-to-bedside research to identify the biological hallmarks of #rarecancers such as #RenalMedullaryCarcinoma can turn the impossible into reality. Kidney Cancer Chris Johnson Foundation Inc. R.M.C. Inc Dr. Kimryn Rathmell KidneyCAN KCCure Rare Cancer Research Foundation + Pattern.org

I need a HUGE favor!! I need you to please send this survey to EVERY M3, M4, or PGY1 (any subspecialty) that you know! luc.co1.qualtrics.com/jfe/form/SV_0S… It takes a few minutes to complete and will give us important data regarding medical education. The purpose becomes clear at the end

Introducing Modern Pathology Special Issue on AI ML and Computational Pathology Led by Hooman Rashidi Liron Pantanowitz and Mathew Hanna as guest editors Regulatory Aspects of AI-ML sciencedirect.com/science/articl…

Metanephric adenoma with papillary architecture-Key to diagnosis is primitive blue cells with uniform nuclei; positive BRAFv (shown in pictures),positive CD57. Main d/d-papillary RCC which are more pleomorphic, prominent nucleoli , BRAFv negative, CD57-. ncbi.nlm.nih.gov/pubmed/25602792

Urothelial Papilloma-papillary neoplasm, minimal branching, lined by normal urothelium, prominent umbrella cells(here vacuolated),no significant cytologic atypia; in younger pts,benign course,rare recurrence(<10%);important not to overcall as #BladderCancer Michigan Pathology #Pathology